Oncology trial operations

Colorectal cancer clinical trial operations

In a postoperative colorectal cancer study, a blood draw can depend on the actual resection date and an available tissue specimen. In a metastatic cohort, the dependency may be a qualifying molecular result and prior treatment record.

Where study execution gets difficult

A postoperative circulating tumor DNA (ctDNA) study may route resection tissue and a later blood sample to the laboratory through different teams. A change to the actual surgery date can change the draw window and the time available for results. The NCI-listed CIRCULATE–North America study is one example of research testing postoperative ctDNA in colon cancer.

What the study team can do

Record the actual procedure date and recalculate the collection window using the protocol. Have the CRA reconcile collection, dispatch, receipt, and lab status. Have the CTM track the result deadline against the study milestone and coordinate action with the site and laboratory when the timeline is at risk.

When this handoff needs a sponsor decision, use an executive briefing to clarify who owns it and what evidence will guide the decision.

Request an executive briefing →

What each role can own

Oncology CRA

Check the surgery date, collection date, shipping record, and lab receipt against the protocol and lab manual.

CTM or Clinical Study Manager

Track pending results against the enrollment or randomization milestone and coordinate site and lab follow-up.

Cross-site monitoring review

Distinguish late postoperative draws, insufficient tissue, courier exceptions, and lab turnaround before deciding where to intervene.

A Lead CRA can coordinate recurring findings. For scoped SIGNAL Managed Monitoring, a named review lead brings patterns and open actions to the sponsor’s decision owners.

What to put in the staffing brief

  1. Identify who confirms the actual resection date and who updates the postoperative draw window when it changes.
  2. List the specimen identifiers and lab statuses the site and central team need to reconcile for tissue and blood separately.
  3. Set the escalation point for a late draw, rejected specimen, or pending result. For metastatic cohorts, confirm which assay and treatment history determine screening fit.

Related experience and references